NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

NanoViricides provided added detail on its Phase IIA Ebola trial of NV-387 Oral Gummies in DRC, which began enrolling on or about September 23, 2026, at a cautious pace because NV-387 is a new chemical entity. Phase IIA is designed only to establish a tolerable dosing regimen as a go-no-go gate for a randomized Phase IIB efficacy trial; it is not statistically powered to show efficacy. The company frames the opportunity against a rapidly expanding BDBV outbreak with 4,018 deaths and 8,300 confirmed cases, and no approved treatment or vaccine for the strain, positioning an oral broad-spectrum antiviral as operationally superior to infusion-based rivals like MBP134 and remdesivir.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.